LIC MF Healthcare Fund
Direct · GrowthAI Summary
LIC MF Healthcare Fund has delivered strong SIP returns, with XIRR of 17.2% (1Y), 16.67% (3Y), 18.76% (5Y), and 16.79% (7Y), consistently beating the category average SIP XIRR of 10.6%, 16.2%, 17.44%, and 16.6% respectively. Against the NIFTY 50, the fund shows substantial alpha across horizons, including 14.66% over 3Y and 10.34% over 7Y, while its lump-sum CAGR of 21.14% (3Y) far exceeds the benchmark's 6.46%. The fund has demonstrated genuine outperformance rather than benchmark-hugging, with low beta of roughly 0.53-0.59.
The fund exhibits low beta (0.53-0.59) and a favorable downside capture ratio of 45-53%, meaning it has historically lost less than half as much as the NIFTY 50 in down markets, while upside capture of 59-72% still generated strong alpha. However, it has experienced 4 drawdown events exceeding 10%, with a maximum drawdown duration of 545 days and a recovery period of 239 days, indicating prolonged recovery phases typical of sector funds. Calmar ratios between 0.80 and 0.98 across 1Y to 7Y windows suggest reasonable risk-adjusted returns for a thematic offering.
The portfolio is highly concentrated, with Pharmaceuticals & Biotechnology at 62.7% and Healthcare Services at 30.1%, leaving only 5.7% in Chemicals & Petrochemicals across just 23 total holdings. Sun Pharma (10.09%) and Divi's Laboratories (9.29%) are the largest positions, and the top 10 holdings account for roughly 62.8% of NAV. This focused approach amplifies both sector-specific upside and downside risk, as seen in calendar year swings from +60.43% (2020) to -11.44% (2022).
The fund outperforms the category average SIP XIRR across all comparable horizons, most notably in the 1Y window where its 17.2% XIRR is well above the 10.6% category average. Its 5Y XIRR of 18.76% and 7Y XIRR of 16.79% also edge out category averages of 17.44% and 16.6%, indicating sustained relative strength. A competitive expense ratio of 0.64% for a sector fund further supports its positioning among healthcare-themed peers.
This fund is suitable for investors with high risk tolerance who want targeted exposure to the healthcare and pharmaceutical sector as a satellite holding, not a core portfolio allocation. A time horizon of at least 5-7 years is advisable, given the 545-day maximum drawdown duration and the sector's cyclical calendar-year performance. Investors should be comfortable with periods of significant underperformance, such as the -11.44% return in 2022 and -3.44% in 2025.
- Consistent alpha over NIFTY 50 across all measured horizons, including 14.66% over 3Y and 10.34% over 7Y
- Low downside capture of 45-53% with beta around 0.53-0.59, cushioning losses in weak markets
- SIP XIRR above category averages at every horizon, with a low 0.64% expense ratio
- Extreme sector concentration, with 92.8% of the portfolio in just pharmaceuticals and healthcare services
- Long drawdown recovery cycles, including a 545-day maximum drawdown duration and 239-day recovery, with 4 drawdown events exceeding 10%
Generated on 30-10-2026, 2:15 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹13.07 L | 22.8% | -29.6% | 90.5% |
| 3 Years | ₹36.00 L | ₹45.78 L | 16.5% | -3.5% | 36.0% |
| 5 Years | ₹60.00 L | ₹93.32 L | 18.8% | 11.1% | 25.9% |
| 7 Years | ₹84.00 L | ₹1.50 Cr | 16.8% | 13.9% | 19.1% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 22.8% | 14.3% | 10.5% | +8.5% |
| 3 Years | 16.5% | 11.0% | 16.2% | +5.4% |
| 5 Years | 18.8% | 10.4% | 17.4% | +8.4% |
| 7 Years | 16.8% | 10.6% | 16.6% | +6.2% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 21.7% | 16.6% | -16.3% | 75.2% | 0.67 | 2.23 | 80% | — | — |
| 3 Years | 17.7% | 19.2% | 7.4% | 27.1% | 2.32 | — | 100% | — | — |
| 5 Years | 18.1% | 18.5% | 11.1% | 27.2% | 2.33 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +13.76 | 0.53 | 61.2% | 39.8% | 11.0% | -10.9% |
| 3 Years | +16.01 | 0.59 | 71.5% | 48.6% | 22.4% | 6.4% |
| 5 Years | +7.14 | 0.59 | 64.7% | 52.5% | 12.8% | 5.2% |
| 7 Years | +11.14 | 0.53 | 60.2% | 45.6% | 19.5% | 10.0% |
| 10 Years | +6.71 | 0.52 | 58.7% | 45.1% | 13.8% | 7.5% |
| 12 Years | +4.97 | 0.52 | 58.7% | 45.1% | 11.3% | 6.2% |
| 15 Years | +3.28 | 0.52 | 58.7% | 45.1% | 9.0% | 5.0% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Ltd. | 9.59% |
| 2 | Divi's Laboratories Ltd. | 9.07% |
| 3 | Neuland Laboratories Ltd. | 6.14% |
| 4 | Torrent Pharmaceuticals Ltd. | 6.04% |
| 5 | Apollo Hospitals Enterprise Ltd. | 5.75% |
| 6 | Aurobindo Pharma Ltd. | 5.23% |
| 7 | Navin Fluorine International Ltd. | 4.98% |
| 8 | Zydus Lifesciences Ltd. | 4.97% |
| 9 | Aster DM Quality Care Ltd. | 4.61% |
| 10 | Fortis Healthcare Ltd. | 3.77% |